OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Rayford on Improving Stratification of Patients With Prostate Cancer

February 9th 2019

Walter Rayford, MD, PhD, MBA, a urologic oncologist with the Urology Group and associate professor of medicine at the University of Tennessee West Cancer Center, discusses ways to improve stratification of patients with prostate cancer.

Dr. Holstein on Sequencing Strategies in Myeloma

February 8th 2019

Sarah Holstein, MD, PhD, associate professor of medicine, University of Nebraska, discusses considerations for determining on optimal treatment sequence for patients with myeloma.

Dr. Figlin Discusses Future of RCC Treatment

February 8th 2019

Robert A. Figlin, MD, director, Division of Hematology/Oncology, Steven Spielberg Professor of Biomedical Sciences and Medicine, Cedars-Sinai Medical Center, discusses the future of treatment for patients with renal cell carcinoma.

Dr. Mody Highlights Treatment Advances in HCC

February 8th 2019

Kabir Mody, assistant professor of medicine, consultant, Division of Hematology/Oncology, Mayo Clinic, highlights the recent treatment advances for patients with hepatocellular carcinoma.

Dr. Arora on the Use of Venetoclax in CLL

February 8th 2019

Shagun Arora, MD, assistant clinical professor at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the use of venetoclax (Venclexta) in the treatment of patients with chronic lymphocytic leukemia (CLL).

Dr. Drilon Discusses the Adoption of NGS in Lung Cancer

February 8th 2019

Alexander E. Drilon, MD, medical oncologist at Memorial Sloan Kettering (MSK) Cancer Center, discusses the adoption of next-generation sequencing (NGS) in lung cancer.

Dr. Shah on the Curative Potential of CAR T-Cell Therapy in Myeloma

February 8th 2019

Nina Shah, MD, associate professor of medicine at the University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses the curative potential of chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma.

Dr. Grivas on Checkpoint Inhibitors in Localized Bladder Cancer

February 7th 2019

Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, oncology, University of Washington, Seattle Cancer Care Alliance, discusses the role of checkpoint inhibitors in the treatment of patients with localized bladder cancer.

Dr. Schlumbrecht on Traditional Treatment Approaches for Uterine Leiomyosarcoma

February 7th 2019

Matthew P. Schlumbrecht, MD, associate professor and co-director of Cancer Prevention and Control, Division of Gynecologic Oncology, University of Miami Sylvester Comprehensive Cancer Center, discusses the traditional treatment approaches for patients with uterine leiomyosarcoma.

Dr. Yardley on Importance of Tailoring Treatment to Breast Cancer Subtypes

February 7th 2019

Denise Yardley, MD, senior investigator, Sarah Cannon Research Institute, discusses the importance of tailoring treatment approaches to the different subtypes of patients with breast cancer.

Dr. Kahl on Frontline Therapy Selection in CLL

February 7th 2019

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine, Siteman Cancer Center, discusses frontline therapy selection in chronic lymphocytic leukemia (CLL).

Dr. Berdeja on Maintenance Therapy in Multiple Myeloma

February 7th 2019

Jesus Berdeja, MD, director of Multiple Myeloma Research at Sarah Cannon Research Institute, discusses maintenance therapy in multiple myeloma.

Dr. Kujtan on Frontline Therapy for EGFR-Positive NSCLC

February 7th 2019

Lara Kujtan, MD, assistant professor at the University of Missouri–Kansas City School of Medicine, discusses frontline therapy for patients with EGFR-positive non–small cell lung cancer (NSCLC).

Dr. Gordon Discusses Use of Checkpoint Inhibitors in Hodgkin Lymphoma

February 6th 2019

Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, Northwestern University Feinberg School of Medicine, discusses the use of checkpoint inhibitors in the treatment of patients with Hodgkin lymphoma.

Dr. Kambhampati on Frontline Ibrutinib Plus Obinutuzumab in CLL

February 6th 2019

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Research Institute, discusses the combination of frontline ibrutinib plus obinutuzumab for the treatment of patients with chronic lymphocytic leukemia.

Dr. Goldberg on Treatment Strategies for CNS Metastases

February 6th 2019

Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses treatment strategies for patients with non–small cell lung cancer that develop central nervous system metastases.

Dr. Li on Preoperative Immunotherapy in Hepatocellular Carcinoma

February 6th 2019

Daneng Li, MD, an assistant clinical professor in the Department of Medical Oncology and Therapeutics Research, and a medical oncologist at City of Hope, discusses an ongoing study of preoperative immunotherapy in patients with hepatocellular carcinoma (HCC).

Dr. Fakih Discusses the Utility of Immunoscore in CRC

February 6th 2019

Marwan Fakih, MD, professor, Department of Medical Oncology and Therapeutics Research, associate director for Clinical Investigations, Comprehensive Cancer Center, medical director, Judy and Bernard Briskin Center for Clinical Research, co-director, Gastrointestinal Cancer Program, and section head, Gastrointestinal Medical Oncology, City of Hope, discusses the clinical utility of the Immunoscore in patients with colorectal cancer.

Dr. Valent on Ongoing Research With Immunotherapy in Multiple Myeloma

February 6th 2019

Jason Valent, MD, an oncologist at Cleveland Clinic, discusses ongoing research with immunotherapy, specifically checkpoint inhibitors, in the treatment of patients with multiple myeloma.

Dr. Gieschen on Standard Approaches to Radiation Therapy in Prostate Cancer

February 5th 2019

Holger L. Gieschen, MD, assistant professor, University of Tennessee Health Science Center, radiation oncologist, West Cancer Center, discusses standard approaches to radiation therapy in prostate cancer.